Device Ophthalmology

Precision 1

Payments companies reported to CMS as associated with Precision 1. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$3.6Massociated payments (2023-2025)

12,319clinicians with associated payments

2companies reporting

By year

2023 $970K

2024 $1.5M

2025 $1.1M

Payments reported as associated with Precision 1, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Optometrist $3.5M

Corneal and Contact Management $107K

Ophthalmology $21K

Vision Therapy $4,573

Pediatrics (Optometrist) $3,931

Low Vision Rehabilitation $2,151

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Precision 1

These are the largest totals companies reported as associated with Precision 1. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

Clinician	Location	Specialty	Associated payments (2023-2025)
Sanjay Patel	Apex, NC	Optometrist	$192,320.30
Claudio Lagunas	Houston, TX	Optometrist	$166,129.61
Michael Slusky	North Port, FL	Optometrist	$146,880.58
Susan Resnick	New York, NY	Optometrist	$89,967.70
Jason Compton	New York, NY	Optometrist	$85,556.56
Pamela Lowe	Chicago, IL	Optometrist	$78,833.75
Britt Gustafson	Eden Prairie, MN	Optometrist	$69,500.61
April Jasper	West Palm Beach, FL	Optometrist	$62,010.68
Katie Spear	Defuniak Springs, FL	Optometrist	$58,528.17
Joseph Smay	New Kensington, PA	Optometrist	$50,967.88

Prescribed Precision 1?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

What this means, and what it doesn't

These payments are legal and common. Drug and device makers routinely pay for meals at educational events, consulting, speaking, travel, and research. Companies are required by federal law to report them; that's why this data exists.
A payment is not evidence of wrongdoing. Most clinicians who accept industry payments provide excellent care. Research payments in particular often reflect participation in clinical trials.
Context beats raw numbers. A few hundred dollars in sandwiches over several years is typical. What's worth understanding is scale, source, and purpose, which is what this page shows.
The data comes from companies, not doctors. Figures are "as reported to CMS" by the paying companies. Clinicians can dispute records through CMS's official process.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.